...
首页> 外文期刊>Oncogene >Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers
【24h】

Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers

机译:干细胞转录因子NANOG通过E-钙粘蛋白和FoxJ1的失调控制细胞迁移和侵袭,并导致卵巢癌的不良临床结果

获取原文
           

摘要

Ovarian cancer is the most lethal of all gynecological malignancies, and the identification of novel prognostic and therapeutic targets for ovarian cancer is crucial. It is believed that only a small subset of cancer cells are endowed with stem cell properties, which are responsible for tumor growth, metastatic progression and recurrence. NANOG is one of the key transcription factors essential for maintaining self-renewal and pluripotency in stem cells. This study investigated the role of NANOG in ovarian carcinogenesis and showed overexpression of NANOG mRNA and protein in the nucleus of ovarian cancers compared with benign ovarian lesions. Increased nuclear NANOG expression was significantly associated with high-grade cancers, serous histological subtypes, reduced chemosensitivity, and poor overall and disease-free survival. Further analysis showed NANOG is an independent prognostic factor for overall and disease-free survival. Moreover, NANOG was highly expressed in ovarian cancer cell lines with metastasis-associated property and in clinical samples of metastatic foci. Stable knockdown of NANOG impeded ovarian cancer cell proliferation, migration and invasion, which was accompanied by an increase in mRNA expression of E-cadherin, caveolin-1, FOXO1, FOXO3a, FOXJ1 and FOXB1. Conversely, ectopic NANOG overexpression enhanced ovarian cancer cell migration and invasion along with decreased E-cadherin, caveolin-1, FOXO1, FOXO3a, FOXJ1 and FOXB1 mRNA expression. Importantly, we found Nanog-mediated cell migration and invasion involved its regulation of E-cadherin and FOXJ1. This is the first report revealing the association between NANOG expression and clinical outcome of patients with ovarian cancers, suggesting NANOG to be a potential prognostic marker and therapeutic molecular target in ovarian cancer.
机译:卵巢癌是所有妇科恶性肿瘤中最致命的疾病,因此确定卵巢癌新的预后和治疗靶标至关重要。相信只有一小部分癌细胞具有干细胞特性,这些特性可导致肿瘤生长,转移进程和复发。 NANOG是维持干细胞自我更新和多能性必不可少的关键转录因子之一。这项研究调查了NANOG在卵巢癌发生中的作用,并显示与良性卵巢病变相比,NANOG mRNA和蛋白在卵巢癌核中的过度表达。核NANOG表达的增加与高级别癌症,浆液性组织学亚型,降低的化学敏感性以及较差的总体生存率和无疾病生存率显着相关。进一步的分析表明,NANOG是整体生存和无病生存的独立预后因素。此外,NANOG在具有转移相关特性的卵巢癌细胞系和转移灶的临床样品中高表达。 NANOG的稳定敲低阻碍卵巢癌细胞的增殖,迁移和侵袭,并伴随着E-钙粘蛋白,caveolin-1,FOXO1,FOXO3a,FOXJ1和FOXB1的mRNA表达增加。相反,异位NANOG的过表达增强了卵巢癌细胞的迁移和侵袭,同时降低了E-钙粘蛋白,caveolin-1,FOXO1,FOXO3a,FOXJ1和FOXB1 mRNA的表达。重要的是,我们发现Nanog介导的细胞迁移和侵袭涉及其对E-钙粘蛋白和FOXJ1的调控。这是第一份揭示NANOG表达与卵巢癌患者临床结局之间关系的报告,表明NANOG是卵巢癌的潜在预后标志物和治疗分子靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号